Certara Acquires Pinnacle 21

Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities

July 9, 2024

Software

Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.

Arsenal Capital Partners Invests $449M in Certara

December 8, 2022

Biotechnology

Arsenal Capital Partners closed a previously announced $449 million stock purchase in Certara, acquiring shares from funds controlled by EQT Private Equity and becoming a long-term minority investor. As part of the transaction Arsenal appointed Operating Partner David Spaight to Certara's board while Stephen McLean remains a director; Arsenal agreed to a two-year lock-up on the newly purchased shares.

Merck & Co. Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck & Co., through subsidiary Merck Sharp & Dohme LLC, completed a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per share, making Cidara a wholly owned subsidiary. The acquisition adds Cidara's long-acting antiviral candidate CD388 to Merck's respiratory portfolio and is being accounted for as an asset acquisition.

Certara Acquires Vyasa Analytics

January 4, 2023

AI & Machine Learning

Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.

Sun Life Acquires PinnacleCare

April 23, 2021

Healthcare Services

Sun Life Financial agreed to acquire PinnacleCare, a Maryland-based medical intelligence and health-care navigation provider, for US$85 million to expand its U.S. Stop-Loss & Health business. The acquisition (expected to close mid-2021) will integrate PinnacleCare's care-navigation and second-opinion capabilities into Sun Life's stop-loss offering to improve member outcomes and reduce costs.

Certara Acquires Applied BioMath

December 14, 2023

Biotechnology

Certara, Inc. has acquired Applied BioMath to expand its biosimulation capabilities and establish the life sciences industry's largest quantitative systems pharmacology (QSP) center of excellence. The acquisition combines Certara's biosimulation and AI portfolios with Applied BioMath's proprietary QSP platform and modeling expertise to industrialize QSP and accelerate drug development.